Lawmakers on both the left and right are increasingly blaming pharmacy benefit managers (PBMs) — the intermediaries that negotiate prescription drug prices between manufacturers, insurers, and pharmacies — for rising healthcare costs. Last month, a bipartisan group of legislators reintroduced the Patients Before Monopolies Act, which would prohibit companies that own PBMs from also owning […]
Lawmakers on both the left and right are increasingly blaming pharmacy benefit managers (PBMs) — the intermediaries that negotiate prescription drug prices between manufacturers, insurers, and pharmacies — for rising healthcare costs. Last month, a bipartisan group of legislators reintroduced the Patients Before Monopolies Act, which would prohibit companies that own PBMs from also owning […]
<iframe src="https://statesidedaily.com/embed/cluster/adfcaafa8a176a084748d508e2c8d0164bfef1d5" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Antitrust mistake enters the drug market"></iframe>
